Inhibitor Therapeutics (OTCMKTS:INTI) & Zymergen (NASDAQ:ZY) Head to Head Analysis

Zymergen (NASDAQ:ZYGet Rating) and Inhibitor Therapeutics (OTCMKTS:INTIGet Rating) are both small-cap basic materials companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, earnings, profitability, risk, analyst recommendations and dividends.

Profitability

This table compares Zymergen and Inhibitor Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Zymergen -2,508.94% -93.37% -61.14%
Inhibitor Therapeutics N/A N/A -449.36%

Risk & Volatility

Zymergen has a beta of 2.63, suggesting that its stock price is 163% more volatile than the S&P 500. Comparatively, Inhibitor Therapeutics has a beta of -0.63, suggesting that its stock price is 163% less volatile than the S&P 500.

Earnings & Valuation

This table compares Zymergen and Inhibitor Therapeutics’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Zymergen $16.74 million 13.62 -$361.79 million ($3.55) -0.62
Inhibitor Therapeutics N/A N/A -$300,000.00 N/A N/A

Inhibitor Therapeutics has lower revenue, but higher earnings than Zymergen.

Institutional & Insider Ownership

53.0% of Zymergen shares are held by institutional investors. 11.7% of Zymergen shares are held by insiders. Comparatively, 4.6% of Inhibitor Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings for Zymergen and Inhibitor Therapeutics, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Zymergen 0 6 0 0 2.00
Inhibitor Therapeutics 0 0 0 0 N/A

Zymergen currently has a consensus target price of $6.28, suggesting a potential upside of 186.53%. Given Zymergen’s higher possible upside, equities analysts plainly believe Zymergen is more favorable than Inhibitor Therapeutics.

Summary

Zymergen beats Inhibitor Therapeutics on 6 of the 9 factors compared between the two stocks.

About Zymergen

(Get Rating)

Zymergen Inc. design, develop, and commercialize microbes, molecules, and materials. It offers an automation solution comprising reconfigurable automation carts, a modular hardware building blocks that allow for assembly of work cells customized for the particular needs of a lab; and automation control software, a cloud-based software used to control integrated automation systems. It serves electronics, packaging, healthcare, agriculture, and other industries. Zymergen Inc. was incorporated in 2013 and is based in Emeryville, California.

About Inhibitor Therapeutics

(Get Rating)

Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. It engages in the development of therapies for prostate and lung cancer utilizing SUBA-Itraconazole, an oral formulation of the drug itraconazole; and conducted a positive Phase 2b study of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome. The company was formerly known as HedgePath Pharmaceuticals, Inc. and changed its name to Inhibitor Therapeutics, Inc. in August 2019. Inhibitor Therapeutics, Inc. was founded in 1992 and is based in Tampa, Florida.

Receive News & Ratings for Zymergen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zymergen and related companies with MarketBeat.com's FREE daily email newsletter.